New hip resurfacing device tracked for 10 years in 150 patients

NCT ID NCT06775704

Recruiting now Disease control Sponsor: Medacta International SA Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 150 people aged 18 to 65 who receive the ROMAX hip resurfacing system to treat hip arthritis or dysplasia. Researchers will track how long the implant lasts and how well the hip functions over 10 years. The goal is to monitor the device's safety and performance in real-world use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ROMAX hip resurfacing system (a medical device that resurfaces the hip joint)
What this could lead to: If successful, this could confirm that the ROMAX system is a safe and effective option for younger patients needing hip resurfacing, potentially delaying or avoiding a full hip replacement.
What could go wrong: This is an observational study, not a controlled trial, so results may not prove superiority over other devices. The device may still fail over time, requiring revision surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTHRITIS HIP are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arthritic joint disease developmental dysplasia of the hip developmental dysplasia of the hip 1 Hip Dislocation, Congenital osteoarthritis, hip

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARTHRITIS HIP HIP DYSPLASIA, CONGENITAL

Contacts and locations

Locations

Centre Hospitalier Universitaire de Lille
RECRUITING

Lille, 59000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.